



**Company Contact:  
Richard Gabriel  
CEO and President  
941 366-3400**

**-or-**

**Ron Stabiner  
The Wall Street Group, Inc.  
212-888-4848**

**FOR IMMEDIATE RELEASE:**

## **DNAPRINT GENOMICS SELLS KITS AND RECEIVES POSITIVE FEEDBACK AT RECENT LAW ENFORCEMENT CONVENTIONS**

***DNAWitness™, Retinome™ 2.0 and EUROWitness™ Are Demonstrated and Sold  
as Means to Solve Cold Cases***

**SARASOTA, Fla., Nov. 10, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG)** today announced that, as a result of its attendance at several recent conventions for law enforcement officials, the Company received several strong sales leads and sold several DNAWitness™ kits onsite as it demonstrated how DNA testing can re-open and solve so-called “cold cases.”

“Our attendance at these conventions reinforces our belief in the sizable potential market for DNAPrint’s proprietary DNA products,” stated DNAPrint President and Chief Executive Officer Richard Gabriel. “We continue to invest in these activities because they generate sales and positive leads for future sales. In addition, these meetings allow us to forge valuable, ongoing relationships with law enforcement officials who are genuinely appreciative of our products and services. We look forward to helping them solve ‘cold cases’ in a timely and efficient manner.”

Scientists from DNAPrint Genomics recently returned from The International Associations of Chief of Police (IACP) meeting in Boston and the Mid-States Homicide Investigators meeting in Wichita, where they presented DNAPrint’s signature products - DNAWitness™ 2.5, EUROWitness™ 1.0, and Retinome™ 2.0 - to law enforcement professionals.

“The feedback that we received at each of these meetings was extremely positive,” said Shannon Boyd, Senior DNA Analyst for DNAPrint Genomics. “We generated several sales and received new leads on a number of cases we expect to be working on shortly.

“We’ve seen cases where DNAWitness™ technology has reinvigorated cold investigations and resulted in arrests,” said Matthew Thomas, Ph.D., Senior Scientist at DNAPrint Genomics. “This technology is especially important because it focuses the leads coherently and quickly, allowing the police to focus on a limited set of suspects. In light of DNAWitness™ results, many cases may never end up in the cold case files.”

All three of DNAPrint’s forensic products are suitable for investigations that have biological samples which can be isolated from tissues and blood found at a crime scene, including such items as cigarette butts, hats and gloves.

DNAWitness™ employs patent-pending, database-driven methods to infer elements of physical appearance from crime scene DNA and allow forensic investigators to “paint” molecular portraits

(MORE)

of a suspect. Retinome™ 2.0 can be combined with the DNAWitness™ product to determine a person's eye color. The Company's patent-pending technology identifies additional markers covering newly identified and informative regions of the human pigmentation gene OCA2. EUROWitness™ 1.0 breaks down the four major groupings of Sub Saharan African, Native American, East Asian and Indo-European, providing that a DNAWitness™ 2.5 test comes back with 50% or greater Indo-European. It is capable of further refining the admixture to Northwest European, Southeastern European, Middle Eastern and South Asian.

#### **About DNAPrint Genomics, Inc.**

DNAPrint Genomics, Inc. ([www.dnprint.com](http://www.dnprint.com)) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to [www.dnprint.com](http://www.dnprint.com) for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

#### **Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###